IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$655.51 USD
+14.65 (2.29%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $655.78 +0.27 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IDXX 655.51 +14.65(2.29%)
Will IDXX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IDXX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDXX
Top Analyst Reports for AbbVie, ServiceNow & Boeing
Should You Add IDEXX Stock to Your Portfolio Right Now?
IDXX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Climb Bio, Inc. (CLYM) Stock Outpacing Its Medical Peers This Year?
Why Is Idexx (IDXX) Down 0.4% Since Last Earnings Report?
Idexx Laboratories (IDXX) Recently Broke Out Above the 20-Day Moving Average
Other News for IDXX
Fell Below 20 Day Moving Average appears for IDXX after 0.74% move
Here's How Much $100 Invested In IDEXX Laboratories 20 Years Ago Would Be Worth Today
Is IDXX building bullish momentum? 20 Day Moving Average Support shows up after rising 0.26%
IDXX Crossed Above 20 Day Moving Average on September 15
Tracking Ron Baron's BAMCO Portfolio - Q2 2025 Update